Cyclosporiasis (Cyclospora cayetanensis infection): Comprehensive Research Report

1. Disease Information

Overview: Cyclosporiasis is a foodborne/waterborne diarrheal illness caused by Cyclospora cayetanensis, a coccidian (apicomplexan) protozoan parasite. Humans are the only known host — no animal reservoir has been identified — and transmission occurs via ingestion of sporulated oocysts contaminating fresh produce or water; there is no direct person-to-person transmission because freshly passed oocysts require days-to-weeks of environmental sporulation before becoming infectious (CDC DPDx; PMC6780905, Cyclospora cayetanensis and Cyclosporiasis: An Update).

Key identifiers: - ICD-10-CM: A07.4 (Cyclosporiasis) - MONDO: MONDO:0005725 - Disease Ontology: DOID:12750 - Orphanet: ORPHA210 - SNOMED CT: 240372001 - UMLS: C0343398 - NCBI Taxonomy (organism): Cyclospora cayetanensis, txid88456 - MeSH: Cyclosporiasis (D019022); Organism: Cyclospora (D019081)

Synonyms: Cyclospora infection, Cyclospora cayetanensis infection, "cyanobacterium-like body" (CLB) diarrhea (historical name before speciation in 1993-94), coccidian-associated diarrhea.

Evidence basis: Aggregated disease-level knowledge (case series, outbreak investigations, systematic reviews) predominates; some individual pathologic/histologic case reports exist (e.g., PMID:9395371).

2. Etiology

Causal agent: Infection is caused by ingestion of sporulated oocysts of C. cayetanensis (an obligate intracellular coccidian parasite of the family Eimeriidae). This is an infectious, not genetic, disease — there is no known Mendelian susceptibility locus, though host immune status strongly modulates severity.

A newly recognized taxonomic wrinkle (2023): CDC researchers demonstrated that clinical "C. cayetanensis" cyclosporiasis is actually caused by at least three genetically distinct species/lineages — the classic C. cayetanensis (with lineages A and B distinguished at the CDS3 and 360i2 nuclear loci) plus two novel species, Cyclospora ashfordi sp. nov. and Cyclospora henanensis sp. nov. (isolated from a Henan, China strain), all causing indistinguishable human cyclosporiasis (PMC10090632, Parasitology 2023, "Cyclospora cayetanensis comprises at least 3 species that cause human cyclosporiasis"; CDC AMD success story).

Risk factors: - Environmental/behavioral: Consumption of imported fresh produce (basil, cilantro, raspberries, snow peas, mesclun/salad mix, broccoli), especially from Guatemala, Mexico, Peru; travel to or residence in endemic regions (Guatemala, Peru, Nepal, Haiti, Indonesia, parts of Africa); warm/rainy season exposure — "prevalence...rises during periods of elevated rainfall and warm weather in Guatemala, Honduras, Mexico, Jordan, Nepal, and China" (search synthesis of PMC10536660). - Age: Children in endemic areas show higher susceptibility/prevalence than adults. - Immune status: HIV/AIDS and other immunocompromising conditions (transplant recipients, chemotherapy patients) markedly increase risk of severe, prolonged, and relapsing disease and of extraintestinal (biliary) involvement. - Socioeconomic: Low-income, endemic, or disease-endemic settings with poor water/sanitation infrastructure. - No confirmed genetic risk variants have been described; no GWAS hits are catalogued for cyclosporiasis susceptibility.

Protective factors: No specific genetic protective alleles known. Environmentally, thorough cooking of produce (heat, not chemical disinfection) destroys oocysts; adequate irrigation-water treatment (microfiltration, ozone, UV) reduces field contamination (FDA Cyclospora page; PMC10536660). Repeated natural exposure in endemic areas may confer partial age-related immunity (older residents of endemic areas often show milder/asymptomatic infection versus travelers/children).

Gene-environment interactions: Not established as a specific mechanistic pathway in the literature; the dominant modifiers are host immune competence (HIV, immunosuppression) interacting with environmental oocyst exposure dose/frequency, rather than a defined host genetic polymorphism.

3. Phenotypes

Table (click to expand)

Phenotype	Type	HPO term (suggested)	Notes/Frequency
Watery diarrhea	Symptom	HP:0002014 (Diarrhea)	Hallmark; profuse, often explosive
Abdominal cramping/pain	Symptom	HP:0002027 (Abdominal pain)	Common
Nausea	Symptom	HP:0002018 (Nausea)	Common
Vomiting	Symptom	HP:0002013 (Vomiting)	Occasional
Anorexia/loss of appetite	Symptom	HP:0002039 (Poor appetite)	Common, notable
Weight loss	Sign	HP:0001824 (Weight loss)	Can exceed 20 lb untreated
Fatigue	Symptom	HP:0012378 (Fatigue)	Prominent, often disproportionate
Low-grade fever	Sign	HP:0025336 (Low-grade fever) / HP:0001945 (Fever)	Less common than diarrhea
Bloating/flatulence	Symptom	HP:0002583 (Bowel obstruction) not ideal; consider HP:0030765 (Abdominal bloating)	Common
Myalgias	Symptom	HP:0003326 (Myalgia)	Reported
Malabsorption	Sign	HP:0002024 (Malabsorption)	Documented pathologically
Relapsing/remitting course	Clinical course	(course qualifier, not HP term)	Symptoms wax and wane; may relapse days-weeks after apparent resolution
Guillain-Barré syndrome (rare sequela)	Sign	HP:0002878 (Guillain-Barré syndrome)	Reported post-infectious complication
Reactive arthritis / Reiter syndrome (rare sequela)	Sign	HP:0100558 (Reactive arthritis, if available)	Reported post-infectious complication
Acalculous cholecystitis / biliary disease	Sign	HP:0005375 (Cholecystitis)	Reported in immunocompromised (AIDS) patients

Onset/severity: Incubation averages ~1 week (range 2 days–2+ weeks) (CDC Clinical Overview). Disease is "often mild or asymptomatic" in endemic populations but can be severe in infants, the elderly, and profoundly immunocompromised patients (PMC8471761). Untreated illness can last from several days to a month or longer, with some patients relapsing one or more times.

Quality of life impact: Chronic/relapsing diarrhea with substantial weight loss and fatigue can significantly impair daily functioning, particularly in immunocompromised or pediatric malnourished populations; explicit EQ-5D/SF-36 data specific to cyclosporiasis were not identified in the literature searched.

4. Genetic/Molecular Information

This is an infectious disease with no human causal gene — genetic material of interest belongs to the pathogen itself.

Pathogen genome: The C. cayetanensis nuclear genome is ~44 Mbp, 52% GC content, ~7,500 genes (PMC4851813, comparative genomics study). It also carries a mitochondrial genome (PMID for complete mitochondrial genome: PMC4455993/PLOS ONE 2015) and an apicoplast genome (a relict non-photosynthetic plastid; PMC5129617) — both used as multicopy targets for sensitive detection and geographic traceback.

Comparative genomics: C. cayetanensis shows "coccidia-like metabolism and invasion components but unique surface antigens," with overall genome organization and invasion machinery closely resembling Eimeria tenella, but differing in amino acid metabolism, propanoyl-CoA degradation, GPI-anchor biosynthesis, and N-glycosylation; unlike Eimeria spp., no active LTR-retrotransposons have been identified (PMC4851813).

Genotyping/molecular epidemiology tools (used for outbreak traceback rather than clinical variant calling): - Original MLST panel: five microsatellite loci (CYC3, CYC13, CYC15, CYC21, CYC22) — successful in <60% of stool specimens (search synthesis, PMC8506454). - Newer targeted amplicon deep sequencing (TADS)/targeted amplicon sequencing (TAS) schemes: six nuclear loci (Nu_CDS1–4, Nu_378, Nu_360i2) + two mitochondrial markers (Mt_MSR, Mt_Cmt) (PMID:37396378, PMC10311907, 2023; PMID:38792677, 2024 evaluation of increased genetic resolution). - Mitochondrial junction region typing: successfully typed 132/134 samples into 14 sequence types, matching epidemiologic clusters in 7/10 outbreaks (Emerging Infectious Diseases, 2019). - CDC's ensemble clustering method accounts for sexual recombination in the parasite's life cycle, achieving 90–94% sensitivity/99% specificity for 2019 outbreak clustering.

Species/lineage delineation (2023): Two nuclear loci (CDS3, 360i2) distinguish lineage A vs. B within C. cayetanensis, and a genetically distinct Chinese isolate was elevated to a new species, C. henanensis, alongside C. ashfordi (PMC10090632).

Epigenetics, somatic/germline distinction, chromosomal abnormalities: Not applicable — this is a parasitic infection, not a heritable human genetic disease.

5. Environmental Information

Primary environmental vehicle: Sporulated oocysts contaminating fresh produce (basil, cilantro, raspberries, snow peas, mesclun mix, broccoli) and water. Sporulation requires days-to-weeks at 22–30°C outside the host (PMC8779055).
Infectious agent classification: Protozoan parasite, NCBI Taxonomy ID 88456, phylum Apicomplexa, family Eimeriidae.
Environmental persistence: The oocyst wall confers marked resistance to routine chemical disinfectants, including chlorine — "Cyclospora may be resistant to routine chemical disinfection methods such as those using chlorine" and "routine chemical sanitizers and household produce washes are generally ineffective against Cyclospora oocysts" (FDA Cyclospora page; search synthesis). Only heat (cooking/boiling) reliably destroys oocysts in food; water treatment via microfiltration, ozone, or UV can reduce irrigation-water contamination.
Seasonality: Marked seasonal peaks associated with warm, rainy periods in endemic countries (Guatemala, Honduras, Mexico, Jordan, Nepal, China) and a well-documented May–August seasonal peak in U.S. outbreaks tied to imported produce.
Lifestyle factors: International travel to endemic regions and dietary consumption of imported raw produce are the dominant lifestyle risk factors in non-endemic countries (e.g., U.S., Canada, Europe).

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

Ingestion of sporulated oocysts (via contaminated produce/water) →
Excystation in the gut lumen: sporozoites are released from sporocysts (each sporulated oocyst contains 2 sporocysts, each with 2 elongated sporozoites) →
Invasion of small intestinal (and occasionally biliary) epithelial cells: sporozoites transform into schizonts within a parasitophorous vacuole in the apical cytoplasm, above the host cell nucleus, most numerous at villus tips (PMC8779055; PMID:9395371) →
Asexual schizogony (merogony):
Type I meronts contain 8–12 merozoites (~3–4 µm) that perpetuate autoinfection/amplification within the host intestine.
Type II meronts contain 4 merozoites (~12–15 µm) that differentiate into the sexual stages.
Gametogony: Type II merozoites form microgametocytes (male, flagellated microgametes ~6.6 × 5.2 µm) and macrogametocytes (female, containing eosinophilic wall-forming bodies) →
Fertilization and oocyst formation: unsporulated oocysts (8–10 µm, spheroidal) are shed in feces, non-infectious until environmental sporulation (7–14 days at 22–30°C) completes the cycle →
Local tissue injury: histopathology shows acute-to-chronic inflammatory infiltration of the lamina propria (lymphocytes, plasma cells, eosinophils), surface epithelial disarray, loss of brush border, villous blunting/flattening, crypt hyperplasia, diffuse edema, and vascular dilatation in jejunal biopsies (PMID:9395371; PMC8471761) →
Functional consequence: disruption of the absorptive epithelium produces malabsorptive, secretory watery diarrhea, confirmed pathologically as malabsorption in biopsy-proven cases; inflammatory changes may persist beyond parasitologic clearance, potentially explaining post-infectious relapsing symptoms.
Rare post-infectious immune-mediated sequelae: Guillain-Barré syndrome and reactive arthritis/Reiter syndrome have been reported following cyclosporiasis, suggesting a molecular-mimicry or immune-activation mechanism analogous to other enteric-infection-triggered autoimmune sequelae, though the precise immunologic pathway is not well characterized in the literature reviewed.
Immunocompromised host divergence: in AIDS/transplant patients, parasite burden and tissue spread (including biliary epithelium, producing acalculous cholecystitis and biliary disease) are markedly increased, and clearance requires prolonged/higher-dose antimicrobial therapy.

Cell types involved: small intestinal (jejunal) enterocytes/epithelial cells (CL:0000584 enterocyte; CL:0002250 intestinal crypt cell), biliary epithelial cells (CL:1000343 epithelial cell of intrahepatic bile duct) in immunocompromised hosts, lamina propria lymphocytes and plasma cells (CL:0000542 lymphocyte, CL:0000786 plasma cell).

Biological processes (GO terms): - GO:0044409 (entry into host) / GO:0075732 (viral penetration into host cell, N/A — better: GO:0044412 or general "invasion of host epithelial cell") - GO:0006955 (immune response) - GO:0002526 (acute inflammatory response) - GO:0022415 (viral process — N/A for parasite; use GO:0044403 symbiotic process / host-parasite interaction terms) - GO:0007586 (digestion) — disrupted - GO:0006811 (ion transport) — disrupted absorptive function underlying malabsorption

Protein dysfunction / biochemical abnormalities: Not a host-protein-defect disease; the pathogen's own invasion-related surface antigens are apicomplexan-family unique (distinct from Eimeria), a focus of ongoing genomic characterization (PMC4851813) but not yet resolved to specific therapeutic targets.

Omics/advanced technologies: No single-cell, spatial transcriptomic, or CRISPR functional-genomics datasets specific to C. cayetanensis host-response were identified — a direct consequence of the field's central research bottleneck (see Model Organisms, below): there is no cell-culture or animal model system to propagate the parasite, severely limiting mechanistic/omics studies (PMC10536660; PMC9608778 "Hastening Progress in Cyclospora Requires Studying Eimeria Surrogates").

7. Anatomical Structures Affected

Organ level: Primary target — small intestine (jejunum predominantly). Secondary/complication-level involvement — biliary tract (gallbladder, bile ducts) in immunocompromised hosts. Body system: digestive/gastrointestinal system; secondary neurological (Guillain-Barré) and musculoskeletal/rheumatologic (reactive arthritis) involvement as rare post-infectious sequelae.
UBERON terms: UBERON:0002115 (jejunum), UBERON:0002108 (small intestine), UBERON:0002110 (gallbladder), UBERON:0002394 (bile duct), UBERON:0001007 (digestive system).
Tissue/cell level: Intestinal epithelium (villus and crypt enterocytes), lamina propria (inflammatory infiltrate: lymphocytes, plasma cells, occasional eosinophils), biliary epithelium.
Cell Ontology terms: CL:0000584 (enterocyte), CL:0009017 (intestinal crypt stem cell / crypt epithelial cell), CL:1000343 (epithelial cell of intrahepatic bile duct), CL:0000542 (lymphocyte), CL:0000786 (plasma cell).
Subcellular level: Parasites reside within a parasitophorous vacuole in the apical cytoplasm of host epithelial cells, above the nucleus — GO Cellular Component: GO:0020009 (parasitophorous vacuole membrane) / GO:0033664 (host parasitophorous vacuole).
Localization: Villus tips most heavily parasitized; no clear lateralization pattern (diffuse small-bowel process).

8. Temporal Development

Onset: Incubation averages ~1 week (range 2 days to ≥2 weeks) after ingestion of sporulated oocysts; can affect any age but more severe in infants, elderly, and immunocompromised.
Onset pattern: Acute onset of watery diarrhea and systemic symptoms.
Progression/course: Highly variable — "some patients experience a single self-limited episode, whereas others have waxing and waning symptoms" (PMC8471761). Untreated illness may last days to a month or longer; relapsing course is characteristic, with symptoms resolving then recurring days to a week later, sometimes multiple cycles.
Duration: Self-limited in many immunocompetent hosts over weeks; can become chronic/relapsing in immunocompromised patients (case report of chronic Cyclospora infection with intestinal malabsorption in a heart transplant recipient, PMC12584178).
Remission: Both spontaneous (immunocompetent) and treatment-induced (TMP-SMX) remission occur; inflammatory changes on biopsy may outlast parasitologic cure.
Critical periods: No defined developmental critical window; risk of severe/prolonged disease is driven by immune status rather than age-specific biological windows (though pediatric and elderly hosts trend toward more severe presentations).

9. Inheritance and Population

Not a genetic disease — no Mendelian inheritance pattern, penetrance, expressivity, anticipation, mosaicism, founder effect, or carrier frequency applies.

Epidemiology: - Global prevalence: Pooled worldwide human prevalence estimated at 3.55% in a 2024 systematic review/meta-analysis/meta-regression (Acta Tropica, ScienceDirect, S0001706X24000597); prevalence is markedly higher in low-income/endemic countries and among individuals with diarrhea, particularly in Africa. - Geographic distribution: At least 54 countries have documented C. cayetanensis infections, with outbreaks recorded in 13; high-endemicity regions include Guatemala, Honduras, Peru, Nepal, Haiti, Indonesia, Madagascar, and parts of the Middle East/Asia (Jordan, China). - U.S. burden: In 2023, 4 of 24 (17%) major FDA-investigated foodborne outbreaks were attributed to C. cayetanensis; a June 2023 restaurant-associated outbreak in Limestone County, Alabama produced 47 cases linked to cilantro (PMC12005484; MMWR-style report). 2022 and 2024 showed similar patterns, with the majority of outbreak food-source investigations remaining inconclusive (only broccoli was conclusively confirmed in one 2023 outbreak) (NACMCF 2023 report, FSIS). - Age distribution: Children in endemic countries show higher susceptibility/prevalence than adults; in non-endemic countries, cases cluster among travelers and consumers of imported produce across all ages. - Sex ratio: No strong sex predilection reported in the literature reviewed. - Travelers: C. cayetanensis is a recognized cause of traveler's diarrhea, especially among travelers returning to industrialized countries from endemic regions.

10. Diagnostics

Clinical/laboratory tests: - Microscopy: Stool ova-and-parasite exam with modified acid-fast (Kinyoun) staining — oocysts stain bright pinkish-red, though staining is variable (some mottled, some non-refractile "glassy" and unstained); modified safranin staining offers improved sensitivity and faster turnaround than modified acid-fast; UV autofluorescence microscopy — oocysts autofluoresce blue/green under UV, considered more reliable than acid-fast staining alone. - Molecular (PCR/NAAT): C. cayetanensis-specific PCR assays (e.g., PMC2493149, highly sensitive/specific PCR) and multiplex syndromic gastrointestinal panels (e.g., FilmArray GI Panel) that include Cyclospora targets are increasingly used clinically; molecular methods avoid the sporulation-dependent morphologic ambiguity of microscopy. - Biopsy: Small intestinal (jejunal) biopsy can show diagnostic intracellular parasite stages within parasitophorous vacuoles, though rarely required given stool-based diagnostics. - LOINC: relevant test panels exist for ova-and-parasite exam and GI PCR panels (specific LOINC codes for Cyclospora antigen/PCR are laboratory-specific; Mayo Clinic Labs test CYCL — "Cyclospora Stain, Feces" — is a representative clinical order).

Genetic/molecular epidemiologic testing (not for individual diagnosis but outbreak investigation): targeted amplicon sequencing (TAS/TADS) genotyping panels (nuclear + mitochondrial loci) used by CDC and public health labs for traceback (PMID:37396378; PMID:38792677).

Screening: No population-based or newborn screening programs exist (this is an acute infectious, not congenital/genetic, disease); case-based surveillance and outbreak cluster detection (via PulseNet-style genotyping) function as the "screening" analog at the public-health level.

Differential diagnosis: Other causes of infectious watery diarrhea/traveler's diarrhea — Cryptosporidium, Giardia, Cystoisospora (Isospora) belli, enterotoxigenic E. coli, norovirus, and in immunocompromised hosts, microsporidiosis.

11. Outcome/Prognosis

Mortality: Generally low in immunocompetent hosts; cyclosporiasis is rarely fatal but can cause significant morbidity, especially in malnourished children and severely immunocompromised patients where prolonged, high-volume diarrhea and malabsorption can be life-threatening ("prolonged diarrhea that could be life threatening in immunocompromised patients," search synthesis of clinical reviews).
Morbidity: Significant weight loss (reportedly >20 lb in some untreated cases), fatigue, and malabsorption; chronic cases in immunocompromised hosts (e.g., transplant recipients) can produce sustained intestinal malabsorption (PMC12584178 case report).
Recovery: Excellent with appropriate TMP-SMX treatment (>90% cure rates in immunocompetent patients per PMC8471761); without treatment, illness resolves over days to a month (occasionally longer) but relapse is common.
Complications: Acalculous cholecystitis/biliary disease (especially AIDS patients), Guillain-Barré syndrome, reactive arthritis/Reiter syndrome as rare post-infectious sequelae.
Prognostic factors: Immune status is the dominant prognostic determinant — HIV/AIDS, transplant immunosuppression, and extremes of age (infancy, elderly) predict more severe/prolonged/relapsing disease and treatment courses of longer duration or need for secondary prophylaxis.

12. Treatment

Pharmacotherapy (first-line): - Trimethoprim-sulfamethoxazole (TMP-SMX): treatment of choice. Standard adult regimen: one double-strength tablet (TMP 160 mg/SMX 800 mg) orally twice daily for 7–10 days, achieving >90% cure rates in immunocompetent patients (PMC8471761). In a randomized controlled trial in HIV-infected patients, diarrhea ceased in all 19 TMP-SMX-treated patients, with 18/19 (95%) stool-negative by day 7 (PMID:10836915, comparing TMP-SMX vs. ciprofloxacin for Isospora belli and C. cayetanensis in HIV). - HIV-infected/immunocompromised patients: may require longer treatment courses and, in some cases, secondary (chronic suppressive) prophylaxis to prevent relapse. - Alternatives for sulfa allergy: Ciprofloxacin (less effective than TMP-SMX but an acceptable alternative) and nitazoxanide are used when TMP-SMX cannot be tolerated, though treatment failures are more common with these agents; "no highly effective alternatives have been identified for persons who are allergic to or intolerant of TMP-SMX."

MAXO terms: - MAXO:0000647 (chemotherapy) — not applicable; better: generic pharmacotherapy term - Use treatment_term: NCIT:C15986 (Pharmacotherapy) with therapeutic_agent: CHEBI term for trimethoprim/sulfamethoxazole combination (CHEBI:45924 co-trimoxazole), or individual components CHEBI:45963 (trimethoprim), CHEBI:9328 (sulfamethoxazole); ciprofloxacin — CHEBI:100241; nitazoxanide — CHEBI:7580. - MAXO:0000950 (supportive care) for oral rehydration/fluid-electrolyte management.

Advanced therapeutics: None applicable — no gene therapy, cell therapy, RNA-based therapy, targeted therapy, or immunotherapy is used or in development for this parasitic infection.

Surgical/interventional: Not typically required except for management of complications (e.g., cholecystectomy in rare severe acalculous cholecystitis cases).

Supportive care: Oral or IV rehydration and electrolyte repletion for volume losses, nutritional support for malabsorption/weight loss.

Experimental treatments: No dedicated Cyclospora-specific clinical trials were identified as currently active (search of trial-focused sources returned no Cyclospora-specific NCT-registered interventional trials); most evidence base derives from older HIV-era comparative drug trials (e.g., PMID:10836915).

Treatment algorithm: Confirm diagnosis (stool microscopy/PCR) → first-line TMP-SMX 7–10 days → reassess for immunocompromised status (consider extended course/secondary prophylaxis) → for sulfa allergy, ciprofloxacin or nitazoxanide as second-line with counseling on lower efficacy.

13. Prevention

Primary prevention: No vaccine exists. Key strategies: (1) thorough cooking of high-risk imported produce (only heat reliably destroys oocysts, since chlorine and standard produce washes are largely ineffective against the resistant oocyst wall); (2) safe drinking-water practices, especially for travelers to endemic regions; (3) improved agricultural practices — sanitized irrigation water, water treatment via microfiltration/ozone/UV in growing regions (FDA; PMC10536660).
Secondary prevention (screening/early detection): No population screening program exists; clinical suspicion in returning travelers or after implicated produce exposure prompts stool testing; outbreak surveillance and genotyping-based traceback (CDC's TAS/mitochondrial-junction methods) functions as public-health-level early detection to halt ongoing exposures.
Tertiary prevention: Prompt TMP-SMX treatment to prevent complications (biliary disease, prolonged malabsorption) and, in immunocompromised patients, secondary prophylaxis to prevent relapse.
Public health interventions: FDA/CDC foodborne-outbreak investigation infrastructure (PulseNet-style genotype clustering), import controls/testing on high-risk produce commodities from endemic-growing regions, and grower-level Good Agricultural Practices (GAP) guidance (2023 NACMCF report on Cyclospora in produce).
Traveler's health counseling: Avoid unpeeled/unwashed raw produce and untreated water in endemic destinations.
Genetic counseling: Not applicable (non-genetic disease).

14. Other Species / Natural Disease

Host range: Humans are the only known definitive host for C. cayetanensis sensu stricto; extensive experimental attempts to infect a wide variety of animal models (including non-human primates) have failed (PMC8779055; PMC10536660).
Related organisms in animals: Numerous other Cyclospora species infect non-human hosts (reptiles, rodents, other mammals) but do not cause human disease; a molecular survey found Cyclospora spp. in cattle in Shanxi Province, China (PMC11274234), raising open questions about environmental/zoonotic overlap that remain unresolved for human-infective genotypes specifically.
Newly named species (2023): Cyclospora ashfordi sp. nov. and Cyclospora henanensis sp. nov., both shown to cause human cyclosporiasis alongside classic C. cayetanensis lineages A/B (PMC10090632) — an important taxonomic/comparative-biology update.
Transmission/zoonotic potential: No confirmed zoonotic transmission cycle for the human-infective Cyclospora species/lineages; the human-only host cycle is a key epidemiologic feature distinguishing cyclosporiasis from cryptosporidiosis (which does have zoonotic reservoirs).
Comparative biology: Genomically and morphologically, C. cayetanensis is closely allied with Eimeria (94–98% SSU rRNA sequence similarity), particularly avian-infecting Eimeria species, and shares coccidia-like metabolic and invasion machinery with Eimeria tenella despite unique surface antigens (PMC4851813).

15. Model Organisms

This is the single greatest research bottleneck for the disease:

No validated animal model exists. "Researchers have been unable to establish C. cayetanensis infection in a wide variety of animal models," and there is no in vitro/tissue-culture propagation system either (PMC10536660; PMC9608778).
Human challenge study: A CDC pilot human-challenge study (PMID:15200870, Emerging Infectious Diseases 2004) dosed 7 healthy volunteers with 200–49,000 oocysts; none developed clinical or parasitologic evidence of infection over 16 weeks of follow-up — underscoring major unknowns in infectious dose, host susceptibility factors, and possibly reduced oocyst viability by the time of the challenge inoculum.
Surrogate model strategy: Given the impasse, researchers have proposed using the genomically and biologically related genus Eimeria (which does have established animal infection models, e.g., E. tenella in chickens, E. falciformis in mice) as a tractable surrogate system to model coccidian biology relevant to Cyclospora — see PMC9608778, "Hastening Progress in Cyclospora Requires Studying Eimeria Surrogates."
Available research material: Investigators must rely entirely on oocysts recovered from naturally infected human stool specimens, which are scarce, variably viable, and logistically difficult to standardize — severely constraining functional genomics, drug-screening, vaccine development, and mechanistic host-response studies.
Resources: No dedicated Cyclospora model-organism repository/database exists analogous to MGI/ZFIN/FlyBase for this pathogen; genomic resources are housed in general databases (NCBI Taxonomy txid88456, GenBank genome assemblies referenced in PMC4851813, PMC4455993, PMC5129617).

Summary of Key Ontology Term Suggestions